Cumberland Pharmaceuticals Inc.

Total Valuation

Cumberland Pharmaceuticals Inc. carries a market capitalization of 101.74M, placing it among publicly traded companies globally. Its enterprise value stands at 97.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cumberland Pharmaceuticals Inc. currently has 14.98M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 3.10, and the price-to-book ratio stands at 5.57.

Enterprise Valuation

On an enterprise value basis, Cumberland Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 39.56 and an EV/FCF ratio of 33.04. The EV/Sales ratio of 3.12 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 73.96 provides insight into valuation relative to core operating earnings.

Financial Position

Cumberland Pharmaceuticals Inc. maintains a current ratio of 0.96, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.56, indicating elevated leverage, while an interest coverage ratio of -14.06 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Cumberland Pharmaceuticals Inc.'s stock has gained approximately 105.13595% over the past 52 weeks. The 50-day moving average sits at 7.22, while the 200-day moving average is 4.81.

Income Statement

Over the trailing twelve months, Cumberland Pharmaceuticals Inc. generated 31.27M in revenue and converted that into -10.92M in net income, yielding earnings per share of -0.65. EBITDA reached -4.35M, while operating income came in at -9.63M.

Balance Sheet

Cumberland Pharmaceuticals Inc. holds 3.86M in cash and equivalents against 4.71M in total debt, resulting in a net debt position of -3.86M. Total book value stands at 17.44M, with working capital of -1.55M providing operational flexibility.

Cash Flow

Cumberland Pharmaceuticals Inc. produced 745,969.00 in operating cash flow over the past twelve months. After subtracting -1.90M in capital expenditures, free cash flow totaled -1.15M - equivalent to -0.08 per share.

Margins

Cumberland Pharmaceuticals Inc. operates with a gross margin of 83.49, reflecting its pricing power and cost economics. The operating margin of -30.79 and net profit margin of -34.92 provide insight into operational efficiency.

Dividends & Yields

Scores

Cumberland Pharmaceuticals Inc. posts an Altman Z-Score of 0.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.